Video

Multiple myeloma precursor conditions | Eva Medvedova, MD

Posted by
HealthTree Logo HealthTree
• November 24, 2026

Description

In this presentation from the HealthTree Portland Myeloma Roundtable (November 7, 2026), Eva Medvedova, MD of OHSU Knight Cancer Institute explains how AL amyloidosis can occur alongside multiple myeloma, what warning signs patients should watch for, and how both conditions are diagnosed and treated.

Key topics covered in this session:

• How light chain (AL) amyloidosis relates to multiple myeloma and plasma cell disorders

• Early symptoms to watch for, including unexplained shortness of breath, fatigue, swelling, or neuropathy

• Diagnostic testing and modern treatment approaches for patients with overlapping myeloma and amyloidosis

Timestamps:

0:00 Introduction & Talk Overview

0:52 Plasma Cells & Precursor Conditions

3:58 When to Treat Smoldering Myeloma

6:10 High-Risk Smoldering Risk Factors

8:22 Genetic Markers & New Risk Models

10:09 Active Surveillance vs Early Treatment

11:58 Daratumumab for Smoldering Myeloma

15:43 Bispecific & CAR T Trials

18:31 To Treat or Not to Treat

20:00 AL Amyloidosis & Light Chains

22:04 Symptoms of Amyloidosis

25:23 Diagnosing Amyloidosis

Event details: https://healthtree.org/events/portlandrt2026

Transcript

my talk is actually. What is it? Where does the myeloma come from? And so we'll be discussing the precursors to multiple myeloma now. So what are the precursor conditions? How do doctors identify high risk smoldering myeloma? How are management strategies evolving in the high risk smoldering myeloma patients? And what else can happen as a result of the that these abnormal cells and the abnormal proteins? So first to get us started where does this all come from? So all healthy people have a type of white blood cells that is called a plasma cell. And you see it on the top left of the green slide. It's a beautiful, healthy plasma cells. We have all of us have a multitude of different plasma cells that will make different antibodies that help us fight different infections as we go through life. And unfortunately, in some cases, as we go through life, one of these cells will start developing, genetic changes and will start to grow out of control. So there is too many of these cells, a clone of cells. So the healthy bone marrow, plasma cells are replaced by these abnormal, kind of precancerous plasma cells. These cells will retain the property of making antibody like proteins and those we can detect in the blood urine. And Doctor Silberman nicely explained to you that we use test called serum electrophoresis for ACS, where you can find this M spike in these states where patients still does not have multiple myeloma, but has accumulated these clones of plasma cells. These conditions are most often asymptomatic and are called precursor plasma cell conditions. Monoclonal gammopathy of undetermined significance. That is, on the left side. And in that case, a patient, will or a person, relatively healthy person will have a small percentage of these clonal plasma cells in their bone marrow. We will be able to detect a small number of these abnormal proteins in the blood. And most importantly, the person will not have any symptoms that are related to these abnormal cells. Now, over time, as things may change, there may be a growth of these plasma cells. There is more of them. And as this evolves over time, patients may develop what we call smoldering multiple myeloma. This is defined as then at least 10% of plasma cells in the bone marrow and less than 60%. The proteins are higher. And again, there should be no symptoms related to this. On the right side, you see the picture depicting multiple myeloma where there is a significantly greater number of cells, higher numbers of proteins. And most often there are symptoms that you have all heard about. Now who decides when should we treat these conditions? So historically, we have always treated multiple myeloma at a point where there was a clear problem. There was a bone fracture, patient was anemic and tired. Because of that, the kidney function became abnormal. That has changed in 2014. In 2014, by then, we have developed all these exciting new treatments that not only work well, but also don't have that many side effects. So, the smart doctors from all around the world who treat myeloma decided that we should actually not wait. And some of the patients in the smoldering myeloma, when they have a really high risk of developing myeloma in the next few years. Those are the patients that we should also treat. So we have added some additional criteria to the so-called CRAB criteria. And if a person with smoldering myeloma has at least 60% of plasma cells in the bone marrow, or if they have at least two tiny spots on the MRI that are suggestive of myeloma, those are patients that we should also treat. There is another one that is called serum free light chain ratio greater than 100. That has been always more debatable and has become even more debatable. And is still to be more clarified now. The what I did not show on the prior slides to, well, the patients who have MGUS, monoclonal gammopathy of undetermined significance, they have a low risk of developing multiple myeloma. Over time, it's about 1% per year. In general, the smoldering myeloma, when this first first time this was described, there was a risk that was about 50% time this was described, there was a risk that was about 50% any problems related to these plasma cells in five years. And so that is rather high. And now how can we refine this? We know that many patients, when they are diagnosed with smoldering myeloma, still don't develop symptoms for a really long time, or maybe never, and some really do. So, especially after we carved out the patients with smoldering myeloma in 2014, there has been a need to better define which patients when they have the smoldering myeloma, are truly at a high risk. And we should start thinking about maybe treating them Now, we smart experts all over the world put the data together, and they determined that there are three features to look at. And this determines pretty much, how much cancer or how much the screen cancer's condition is in the body. And what we look at is the three features. One is the abnormal M protein that you saw in the serum protein electrophoresis. And if this is greater than two that is considered one of these risk factors. If the serum free light chain ratio is greater than 20, that is a second risk factor. And if there is at least 20% or more plasma cells in the bone marrow, that is a third risk factor. Now, on the lower part of the slide, you see that if a person with smoldering myeloma does not have any of these features, about six people out of 100 will develop myeloma related condition or need to be treated at two years time. However, if a person will have 2 to 3 of these risk factors, then the risk is quite high and 44 out of 100 patients will develop a symptom or need to be treated in two years. Still means that about 56 will not. Right. So that's the problem with this. So we have been trying further to refine who are the patients that should be treated. And to this we have started analyzing the genetic abnormalities in the abnormal cells. And some of them we have been using in the distinction of myeloma historically before diagnosing them is high risk or not. And some of these include translocation 4;14, translocation 14;16. These are changes between various chromosomes that most often govern the antibody production, something called deletion 17p, deletion of chromosome 1p and abnormalities. Additions of chromosome 1q. This is still not perfect and we need to do much better. Various groups around the world are investigating different approaches. Something called PANGEA model is trying to actually study very carefully, prospectively patients with precursor conditions and create huge databases that will help us try to determine patterns and based on those patterns, predict risk of precursors conditions, turning into a condition that we need to treat. Furthermore, we are using more refined genetic analysis, looking more closer at the genes to again, a little bit better risk. Stratify these questions. And another group in Europe is very actively investigating whether looking and searching for a small fraction of abnormal plasma cells in the blood will help us further refine the risk stratification here. Okay, so moving on after the risk stratification. So how do we currently, manage patients who have smoldering myeloma and specifically high risk myeloma, high risk smoldering myeloma. So for the most of the history of this disease or this condition, precursor condition, we have mostly monitored patients. And we call this active surveillance. When we bring patients in we periodically check the blood work. Sometimes we may check imaging. Sometimes we may repeat the bone marrow biopsy. And most importantly, we also have to talk to the patients periodically to search for possible development of new symptoms. Now, the new thing that we have in smoldering myeloma is something called a control strategy. So we have been trying to use some of the medications that are very effective in treating myeloma and have a relatively low side effect profile to see if we can delay progression to symptoms, and postpone the need for, full indefinite therapy for select patients. And importantly, there are many clinical trials currently ongoing that are trying also to explore the idea well before this is completely causing a lot of problems in its very deranged. Could we actually cure, the disease, the problem at that point now? I this is the next slide are going to talk about one of the strategy that now is validated and not only validated by a clinical trial, but actually approved by the FDA. One of the medication that we use often to treat multiple myeloma is called Dara. And many of you know, it is an antibody. And this antibodies have a relatively low incidence of side effects. So this was felt to be a good idea to see if we can use it in patients who have high risk smoldering myeloma and see if we can prevent symptoms, if we can, make patients, delay the treatment for active myeloma and maybe even cure some of them. Now, this study started over ten years ago, and about 400 patients were studied. About half of them were given very close observation, like we would normally do at this time. And half of the patients receive this medication for three years. What we have seen for the patients who did not get any treatment, we did not see any responses, meaning any improvements in the myeloma proteins over time. For the patients who received the map, we saw some responses. For the patients who received daratumumab, we saw some responses. But despite that fact, we have seen a significant improvement of the patients who developed over time at about five years, active disease that they needed to be treated. So for the patients, there's an example on the left side for the patients who did not get the medications out of 100 patients, 59 of them would have needed to start on treatment. And for the patients who did get the medications, only about 37 of them developed, needed to start the treatment. And so this is felt actually very significant. And based on this information, the FDA has approved the treatment of daratumumab for high risk smoldering myeloma. However, every medication comes with cost. On the left side is the treatment, on the right side is the observation. So patients, when they receive the medications have felt more tired. They have had more colds, they had more diarrhea or arthralgias. There was more sleep problems because there was dexamethasone. And there was slightly higher risk of pneumonia. But the serious side effect, interestingly, profile was not that much different between the two parts of the trial. And definitely we have not seen increased risk of death in the patients receiving the treatment. So however, there is another caveat with this. Not only side effects, but what does progression of smoldering myeloma mean? So interestingly enough, with the close monitoring on this clinical trial, it was extremely infrequent, was so rare that the patients have developed truly something that have impacted their quality of life. Most often we saw number changes, like we saw increase of the serum free light chain ratio, which no one feels right. We saw maybe a tiny spots on the bones on the imaging that also were not symptomatic. Okay, so moving the gears and I will talk a little bit about the clinical trials that, are moving forward right now. And we have some very small amount of studies that, kind of reported on this. You will be hearing in the next sections details about more advanced immune therapies in multiple myeloma. One of one of the types of the immune therapies that we are using in multiple myeloma is called bispecific therapy. And essentially what happens, we are encouraging the patient's own cells to recognize the myeloma and destroy it that way. So one of the preliminary studies that reported out this year showed that if we gave, patient one of these specific antibodies, 42 out of 46 patients did not progress at two years. And 36 out of 46 patients were noted to have the deepest level of remission in a very short period of time. The test that Doctor Silberman so eloquently explained to you. So nothing like what we saw with that. There are two, right? There were no deep responses there. So nothing like, this is really definitely much more, profound effect on the precursor condition. Interestingly enough, when in this trial, this was compared to one of the options that has been out there, and I did not emphasize lenalidomide, the incidence of serious infection was actually not greater than that. And some specific side effects related to the medication. This this inflammatory syndrome that is called cytokine release syndrome was low grade in all the patients. The second exciting immune therapy in multiple myeloma that you will hear later on about is called CAR T, where we use patient's own immune cells to reprogram them to attack the myeloma cells. So this was also used in this setting in a very small number of patients. And all the patients developed the very deep responses. At 15 months, only 15 months. None of these patients developed disease progression. And patients certainly did experience side effects that are associated with this advanced immune therapy. And some of them even experienced this, the worried neurological symptoms and some of them actually they did not resolve fully. They were mild, but they remained. So, to conclude the topic of the smoldering myeloma, I think it is to treat or not to treat is still sort of a question. The patient preference after discussing all the ins and outs is extremely important and is a key the observation strategy. We certainly would favor this in patients who have low to intermediate risk. And this is done through the very careful monitoring that I have described before. And if a patient with low or intermediate risk is interested in treatment, that should be done solely in the context of clinical trials. On the other hand, treatment can be considered in patients who have high risk smoldering myeloma, and those B usually set the cutoff at the high risk of progression of 50% at two years. And here we think that the treatment can delay and may prevent damage over time. But still, there are probably some patients that would have never developed symptoms. And we have treated and if we do want to do the treatment. So currently the only approved treatment is with the map So currently the only approved treatment is with daratumumab If one is interested in a more advanced treatment that potentially leads to cure, then clinical trial is the only way. How to get to that. Now, this is changing the gears a little bit, going back to the precursor conditions, and I have talked a lot about how the precursor conditions turn into the myeloma, but that may not always be the case. Sometimes the precursor conditions actually turn into a different problem that needs to be treated. And in this case, one of the cases, one of the most common cases is something called amyloidosis. And in this case, it's actually not a problem of abnormal cells, but it is more problems of the proteins. So if we remember back. If we remember back about the antibody molecule that we have looked at before. So each antibody molecule has a I don't think I can ever operate the pointer. So I'll speak without it. So the antibody molecule has this Y structure. And you see it's the Y. And then you have this tiny pieces attached to it. And those are light chains. So in the case of this condition that I'm talking about called AL amyloidosis, this protein changes shape. We say it misfolded. It doesn't have a proper organized structure. And once this happens, these amyloid proteins stick together and they go through the bloodstream, and they can deposit in various parts of the body. Now, the problem with this condition is that sometimes the patient may have a low amount of the abnormal proteins in the blood. When we compared with multiple myeloma or even smoldering myeloma. And despite that fact, there is this peculiar property of the light chains that they make them misfolded. What are the symptoms of amyloidosis? So most symptoms are extremely common. And they can frequently occur with other conditions. But some of these are rather rare. So let me start with the characteristic ones that are rare. So one of them you will see on the top right, both of them on the top right side of the slide. And you see this patient who has this bruises around the eyes. So that is extremely, typical, very uncommon, but typical. And the second one is that the patients may have a larger tongue. And when they have enlarged tongue, sometimes it can lead to difficulty swallowing. It can make their speech be a little bit muffled. And you may see imprints of the teeth on the side of the tongue as well. Now, the more typical side effects are very nonspecific, meaning they can happen in many other conditions. And that's why they are really hard to recognize. So some of the symptoms that are the common and nonspecific include tiredness, fatigue. Right. And who is not tired when they are working or going through their life. The one to pay attention to is. So if, slowly a person is developing shortness of breath, and particularly it is getting really hard with exercise. So we have had many patients that are doing a lot of running and suddenly they can barely walk from, their bedroom to the bathroom. So that's a big difference and huge change to pay attention to our Bisley. And like swelling is very common with this condition for various reasons, because sometimes the heart may not be working, sometimes the kidneys may not be working. And one of the ones that is interesting, many as you as you probably know, many people have high blood pressure. If over time one of my patients develop say, oh yeah, I no longer need those blood pressure medications. And there were on many blood pressure medications before, that could be one of the, things to think about. Or could this patient be developing amyloidosis? Patients with amyloidosis also frequently have neuropathy. Doctor Silverman also describes some of the symptoms of neuropathy. And the most commonly we see numbness tingling, burning sensation in the hands or feet. numbness tingling, burning sensation in the hands or feet. not feeling dizzy, lightheaded and not feeling like you are going to pass out, which we call, which is a change in the blood pressure that the blood pressure does not increase appropriately when a person stands up. And that is called orthostatic hypotension. And another common one would be foaming of the urine because of the deposition of these abnormal proteins in the kidneys, the kidneys become leaky and spill a lot of protein into the urine. Okay. So evaluation is for amyloidosis is a little bit different. I mean it does focus on a workup for the for the plasma cell disorder, for the myeloma like workup. And we always have to look at the heart function, kidney function. We do sometimes nerve testing. But how can we achieve the diagnosis. So we have patients who may have this suspicion symptoms. They may have this abnormality in the blood. We do need to confirm that the person has amyloidosis by doing special biopsy. Where we prove this. And many times we are successful confirming this diagnosis by using a combination of fat pad biopsy and a bold biopsy. But sometimes we may resort to obtain a kidney biopsy or a heart biopsy. And pathologist, when we are suspecting this condition, we need to ask them specifically that they do a special stain called Congo red. And you will see that the green picture on the lower part on the right side of the slide, that's how the amyloid looks under the special microscope. And that kind of serves us to confirm amyloidosis. And I believe I'm done for you in as early. Thank you.